The investor call confirms strong operational momentum in Tempus's MRD business ahead of the Personalis acquisition. Monitor the Q2 earnings call on July 30 for financial impact details and updated guidance. Key milestones to watch: Personalis shareholder vote, HSR clearance, and Tempus's ability to expand MRD sales force and improve reimbursement rates.
Price Chart
Executive Summary
Tempus AI (TEM) filed a 425 investor call transcript reinforcing its July 20, 2026 definitive agreement to acquire Personalis (PSNL). The call highlighted NeXT Personal MRD test volumes growing 38% QoQ to ~9,000 tests in Q2, with only 10% of Tempus's sales force currently selling the assay, suggesting significant runway for expansion. The $1.5B net stock-for-stock deal is expected to close late 2026 or early 2027, with Tempus reiterating its 2027 EBITDA and FCF positivity target.
Key Financial Metrics
Key Facts
- Tempus acquiring Personalis at $16.25/share, representing a 6% premium to Friday's close and 28% premium to the 30-day VWAP; total consideration $1.5B net of existing stake
- NeXT Personal MRD test volumes grew 38% QoQ to ~9,000 tests in Q2 2026 (from ~6,500 in Q1)
- Only 10% of Tempus's sales force currently sells MRD solutions, indicating future volume growth potential as more reps are equipped
- Consideration structured as 100% stock with Tempus option to pay up to 50% in cash; floating exchange ratio capped at 0.3356
- Closing expected late 2026 or early 2027, subject to Personalis shareholder approval, HSR clearance, and other conditions
- Tempus intends to be EBITDA and free cash flow positive in 2027 even with the acquisition
Financial Impact
$1.5B net acquisition value; NeXT Personal MRD test volumes growing 38% QoQ with significant sales force expansion potential
Risk Factors
- Personalis is still burning cash (~$20M+ per quarter as noted in the Q&A); integration may delay Tempus's path to profitability
- Shareholder approval and regulatory clearance (HSR) are required; any delay could push close beyond early 2027
- Market price of TEM below $46.00 gives Personalis a termination right, adding price risk
- Competitive pressure from Natera and other MRD players could limit market share gains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-309096 |
| Document: 0001193125-26-309096-index-headers.html | 0001193125-26-309096 |
| Document: 0001193125-26-309096-index.html | 0001193125-26-309096 |
| Document: 0001193125-26-309096.txt | 0001193125-26-309096 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Insider Cluster | $64.62 $62.21 | ▼ −3.73% | ▼ −2.52% | $76.63 (+18.59%) |
Sep 3, 2026 29d ago | Insider Cluster | $64.62 $62.21 | ▼ −3.73% | ▼ −2.52% | $76.63 (+18.59%) |
Sep 1, 2026 4w ago | Insider Cluster | $62.27 $61.28 | ▼ −1.59% | ▼ −1.67% | $76.63 (+23.06%) |
Aug 28, 2026 5w ago | Insider Cluster | $64.04 $64.62 | ▼ −0.91% | ▼ −0.80% | $76.63 (−19.66%) |
Aug 25, 2026 5w ago | 144 | $68.48 $61.94 | ▲ +9.55% | ▲ +9.43% | $76.63 (−11.90%) |
Aug 25, 2026 5w ago | Insider Cluster | $68.73 $62.27 | ▼ −9.40% | ▼ −8.86% | $76.63 (+11.49%) |
Aug 21, 2026 6w ago | Insider Cluster | $72.69 $64.04 | ▲ +11.90% | ▲ +12.37% | $76.63 (−5.42%) |
Aug 19, 2026 6w ago | 144 | $66.65 $70.69 | ▲ +6.06% | ▲ +4.95% | $76.63 (+14.97%) |
Aug 18, 2026 6w ago | Insider Cluster | $49.36 $68.73 | ▼ −39.24% | ▼ −39.44% | $76.63 (−55.25%) |
Aug 11, 2026 7w ago | Insider Cluster | $55.69 $49.36 | ▼ −11.37% | ▼ −10.96% | $76.63 (+37.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access